WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke Letybo wurde als Wortmarke am 13.06.2019 bei der Weltorganisation für geistiges Eigentum angemeldet.
| Markenform | Wortmarke |
| Aktenzeichen | 1484345 |
| Länder | 
|
| Basismarke |
Nr. ,
16. August 2024
|
| Anmeldedatum | 13. Juni 2019 |
| Ablaufdatum | 13. Juni 2029 |
Markeninhaber
61-20, Sinbuk-ro,
Sinbuk-eup,
KR
Sinbuk-eup,
KR
Markenvertreter
23rd Floor, D-Tower (D2),
17 Jongno 3-gil,
KR
Waren und Dienstleistungen
05
Pharmaceutical preparations for the treatment of smooth
muscle disorders, autonomic nerve disorders, sports
injuries, cerebral palsy, tremors and pain; injectable
dermal fillers; pharmaceutical products for skin care for
animals; pharmaceutical preparations for use in treating
urogenital system diseases and conditions, namely,
overactive bladder and urinary incontinence; pharmaceutical
preparations for treating peripheral neurological diseases
and disorders; pharmaceutical preparations for treating
central neurological diseases and disorders; medicated
ointments for treating dermatological conditions; cultures
of microorganisms for medical or veterinary use; chemical
reagents for medical or veterinary purposes; bacteriological
preparations for medical and veterinary use; adjuvants for
medical purposes; hyaluronic acid preparations for medical
purposes; medicines for human purposes; pharmaceutical
preparations for the treatment of psychiatric diseases and
disorders; pharmaceutical preparations for use in
orthopedics; pharmaceutical preparations; pharmaceutical
preparations for the treatment of wrinkles; injectable
dermal fillers, namely injectable pharmaceutical products
for intradermal use; medicines for dental purposes;
pharmaceutical preparations for the treatment of pain;
pharmaceutical preparations for use in dermatology;
pharmaceutical preparations for treating skin disorders;
pharmaceutical preparations mainly based on hyaluronic acid;
therapeutic drugs and agents; pharmaceutical preparations
for the treatment of psychiatric diseases, namely, mood
disorders, anxiety disorders, cognitive disorders and
schizophrenia; pharmaceutical preparations for the treatment
of spasm; pharmaceutical preparations for treating dystonia;
muscle relaxants; pharmaceutical preparations for the
treatment of hyperhidrosis; pharmaceutical preparations for
animals; pharmaceutical preparations for the treatment of
headache; pharmaceutical preparations used in cosmetic
surgery; pharmaceutical preparations containing botulinum
toxin; botulinum toxin; pharmaceutical preparations
containing botulinum toxin for the treatment of wrinkles;
pharmaceutical preparations containing botulinum toxin
fragments for the treatment of wrinkles; pharmaceutical
preparations for use in treating urogenital system diseases
and conditions; bacterial toxins; pharmaceutical
preparations for digestive system; pharmacological
preparations for skin care; pharmaceutical preparations for
treating neurological diseases and disorders; ophthalmic
preparations; ointments for pharmaceutical purposes;
chemical preparations for pharmaceutical purposes;
pharmaceutical agents for epidermis; drugs for medical
purposes; biological preparations for medical or veterinary
purposes; microorganisms for medical purposes; chemical
preparations for phamaceutical purposes for the treatment of
neurological disorders, muscle dystonias, smooth muscle
disorders, autonomic nerve disorders, headaches, wrinkles,
hyperhydrosis and cerebral palsy; chemical preparations for
phamaceutical purposes for the treatment of sports injuries,
namely, injured or torn skin, muscle, ligaments or bone;
chemical preparations for phamaceutical purposes for the
treatment of tremors, namely, spasmodic smooth, striated or
cardiac muscles; chemical preparations for phamaceutical
purposes for the treatment of pain, namely, smooth muscle
pain, striated muscle pain, cardiac muscle pain, neuropathic
pain, inflammatory pain, visceral pain, chronic pain, acute
pain, traumatic injury pain, referred pain, growing pain,
hunger pain, intractable pain, labour pain, organic pain,
phantom limb pain, postprandial pain, psychogenic pain, back
pain, post-stroke pain, cancer pain, nociceptive pain,
headache pain, prostatic pain, and bladder pain; drugs for
medical purposes for the treatment of neurological
disorders, muscle dystonias, smooth muscle disorders,
autonomic nerve disorders, headaches, wrinkles,
hyperhydrosis and cerebral palsy; drugs for medical purposes
for the treatment of sports injuries, namely, injured or
torn skin, muscle, ligaments or bone; drugs for medical
purposes for the treatment of tremors, namely, spasmodic
smooth, striated or cardiac muscles; drugs for medical
purposes for the treatment of pain, namely, smooth muscle
pain, striated muscle pain, cardiac muscle pain, neuropathic
pain, inflammatory pain, visceral pain, chronic pain, acute
pain, traumatic injury pain, referred pain, growing pain,
hunger pain, intractable pain, labour pain, organic pain,
phantom limb pain, postprandial pain, psychogenic pain, back
pain, post-stroke pain, cancer pain, nociceptive pain,
headache pain, prostatic pain, and bladder pain; biological
preparations for medical or veterinary purposes for the
treatment of aesthetic dermatology, orthopaedics, arthritis
and ophthalmology; medicines for human purpose, namely
medicines for skin care; pharmaceutical preparations for the
treatment of orthopaedic disorders, namely hip dislocation,
spinal column deformation, curvature of the spine namely
scoliosis, lordosis, cyphosis; pharmaceutical preparations
for smooth muscle disorders, autonomic nerve disorders,
headaches, hyperhydrosis, sports injuries, cerebral palsy,
tremors and pain; preparation for the relief of pain;
pharmaceutical preparations mainly based on hyaluronic acid
for treatments namely injectable for intradermal and
subcutaneous application for facial and body skin tightening
and smoothing; botulinum toxin for medical use for use in
the treatment of excessive sweating, excessive eye blinking,
neuropathy pain, facial wrinkles, headache, pain, spasm,
dystonia, urogenital system diseases and conditions, skin
disorders; pharmaceutical agents affecting digestive organs;
biological preparations for medical purposes; biological
preparations for veterinary purposes; chemical reagents for
medical purposes; chemical reagents for veterinary purposes;
bacterial preparations for medical purposes; bacterial
preparations for veterinary purposes; therapeutic creams
[medical]
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 13. Juli 2023 | 2023/28 Gaz | NO | Ablehnung |
| 19. Juni 2023 | 2023/25 Gaz | CH | Ablehnung |
| 27. April 2023 | 2023/17 Gaz | ME | Ablehnung |
| 20. Februar 2023 | 2023/8 Gaz | RS | Ablehnung |
| 08. August 2022 | 2022/40 Gaz | PH | RAW: Total Invalidation |
| 05. Juli 2022 | 2022/30 Gaz | Korrektur | |
| 11. April 2022 | 2022/16 Gaz | MX | Ablehnung |
| 06. September 2021 | 2021/37 Gaz | EM | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 06. Februar 2021 | 2021/7 Gaz | US | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 31. Januar 2021 | 2021/6 Gaz | TH | Ablehnung |
| 23. Dezember 2020 | 2020/52 Gaz | TR | Ablehnung |
| 06. November 2020 | 2020/46 Gaz | ID | Ablehnung |
| 01. Oktober 2020 | 2020/40 Gaz | JP | Ablehnung |
| 21. September 2020 | 2020/42 Gaz | IN | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 02. September 2020 | 2020/38 Gaz | IL | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 21. August 2020 | 2020/35 Gaz | AM | Ablehnung |
| 20. August 2020 | 2020/34 Gaz | VN | Ablehnung |
| 18. August 2020 | 2020/35 Gaz | KG | Ablehnung |
| 14. August 2020 | 2020/34 Gaz | GE | Ablehnung |
| 13. August 2020 | 2020/33 Gaz | KZ | Ablehnung |
| 30. Juli 2020 | 2020/31 Gaz | UA | Ablehnung |
| 28. Juni 2020 | 2020/27 Gaz | DZ | Ablehnung |
| 03. Juni 2020 | 2020/23 Gaz | CO | Ablehnung |
| 19. Mai 2020 | 2020/21 Gaz | BY | Ablehnung |
| 31. März 2020 | 2020/14 Gaz | MN | Ablehnung |
| 19. Februar 2020 | 2020/8 Gaz | AU | Ablehnung |
| 18. Februar 2020 | 2020/9 Gaz | RU | Ablehnung |
| 03. Februar 2020 | 2020/7 Gaz | IL | Ablehnung |
| 17. Januar 2020 | 2020/5 Gaz | EM | Ablehnung |
| 16. Januar 2020 | 2020/3 Gaz | SG | Ablehnung |
| 08. Januar 2020 | 2020/2 Gaz | NZ | Ablehnung |
| 18. November 2019 | 2019/47 Gaz | PH | Ablehnung |
| 08. Oktober 2019 | 2019/44 Gaz | RAW: Limitation | |
| 16. September 2019 | 2019/38 Gaz | US | Ablehnung |
| 09. September 2019 | 2019/37 Gaz | IN | Ablehnung |
| 13. Juni 2019 | 2019/32 Gaz | KR | Eintragung |
ID: 141484345